Curated News
By: NewsRamp Editorial Staff
June 10, 2024
Elicio Therapeutics Unveils Promising Phase 1a Data for ELI-002 7P in mKRAS Tumors
Discuss on Reddit
Discuss on LinkedIn
Discuss on SubstackTLDR
- Preliminary data from Elicio Therapeutics' AMPLIFY-7P Phase 1a Study shows favorable safety profile and early antitumor effects, demonstrating a competitive advantage in treating mKRAS-driven solid tumors.
- ELI-002 7P, a structurally novel investigational Amphiphile (AMP) cancer vaccine, generates a strong T cell response and tumor biomarker reductions, providing a methodical approach to combating mKRAS-driven cancers.
- Elicio Therapeutics' innovative lymph node-targeted immunotherapies show promise in treating aggressive cancers, ultimately empowering patients to fight cancer with full force, making tomorrow better than today.
- The findings from the ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P were presented at the prestigious ASCO Annual Meeting, highlighting the compelling and groundbreaking nature of the research.
Impact - Why it Matters
The preliminary data from Elicio Therapeutics' AMPLIFY-7P Phase 1a Study suggests a potential breakthrough in treating difficult-to-target KRAS mutated cancers, offering hope to patients with aggressive forms of the disease. The innovative approach of using lymph node-targeted immunotherapies and the encouraging early results from the ongoing trials signify a significant advancement in cancer treatment, with the potential to broaden the patient population for the ELI-002 treatment.
Summary
Elicio Therapeutics (NASDAQ: ELTX) has announced that preliminary data from their AMPLIFY-7P Phase 1a Study of ELI-002 7P in patients with mKRAS-driven solid tumors was well tolerated with T cell responses correlating with a reduction in tumor biomarkers at the recommended Phase 2 dose (“RP2D”). Elicio Therapeutics is a clinical-stage biotechnology company focused on developing innovative lymph node-targeted immunotherapies to treat aggressive cancers. The initial findings from its study are encouraging, given that KRAS mutated cancers are difficult to target in part due to the number of diverse mutations and bypass resistance mechanisms.
Elicio Therapeutics’ lead product candidate, ELI-002, is a structurally novel investigational Amphiphile (AMP) cancer vaccine that targets cancers driven by mutations in the mKRAS-gene — a prevalent driver of many human cancers. ELI-002 is currently being studied in an ongoing Phase 1 (AMPLIFY-201) trial in patients with high relapse risk mKRAS-driven solid tumors following surgery and chemotherapy. ELI-002 7P (7 peptide formulation) is being studied in a Phase 1/2 (AMPLIFY-7P) trial in patients with mKRAS-driven pancreatic cancer. The AMPLIFY-7P Phase 1a Study data findings of ELI-002 7P were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, held from May 31 to June 4, 2024, in Chicago, IL.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Elicio Therapeutics Unveils Promising Phase 1a Data for ELI-002 7P in mKRAS Tumors
